These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 29399993)

  • 1. Prediction of factor VIII inhibitor development in the SIPPET cohort by mutational analysis and factor VIII antigen measurement.
    Spena S; Garagiola I; Cannavò A; Mortarino M; Mannucci PM; Rosendaal FR; Peyvandi F;
    J Thromb Haemost; 2018 Apr; 16(4):778-790. PubMed ID: 29399993
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Timing and severity of inhibitor development in recombinant versus plasma-derived factor VIII concentrates: a SIPPET analysis.
    Peyvandi F; Cannavò A; Garagiola I; Palla R; Mannucci PM; Rosendaal FR;
    J Thromb Haemost; 2018 Jan; 16(1):39-43. PubMed ID: 29080391
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In silico calculated affinity of FVIII-derived peptides for HLA class II alleles predicts inhibitor development in haemophilia A patients with missense mutations in the F8 gene.
    Pashov AD; Calvez T; Gilardin L; Maillère B; Repessé Y; Oldenburg J; Pavlova A; Kaveri SV; Lacroix-Desmazes S
    Haemophilia; 2014 Mar; 20(2):176-84. PubMed ID: 24118514
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation between factor VIII genotype and inhibitor development in hemophilia A.
    Fakharzadeh SS; Kazazian HH
    Semin Thromb Hemost; 2000; 26(2):167-71. PubMed ID: 10919409
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of the type of F8 gene mutation on inhibitor development in a single centre cohort of severe haemophilia A patients.
    Gouw SC; Van Der Bom JG; Van Den Berg HM; Zewald RA; Ploos Van Amstel JK; Mauser-Bunschoten EP
    Haemophilia; 2011 Mar; 17(2):275-81. PubMed ID: 21070499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factor VIII genotype and inhibitor development in patients with haemophilia A: highest risk in patients with splice site mutations.
    Boekhorst J; Lari GR; D'Oiron R; Costa JM; Nováková IR; Ala FA; Lavergne JM; VAN Heerde WL
    Haemophilia; 2008 Jul; 14(4):729-35. PubMed ID: 18503540
    [TBL] [Abstract][Full Text] [Related]  

  • 7. F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis.
    Gouw SC; van den Berg HM; Oldenburg J; Astermark J; de Groot PG; Margaglione M; Thompson AR; van Heerde W; Boekhorst J; Miller CH; le Cessie S; van der Bom JG
    Blood; 2012 Mar; 119(12):2922-34. PubMed ID: 22282501
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of F8 inversions as risk factors for FVIII inhibitor development in Indian severe haemophilia A patients.
    Pinto P; Ghosh K; Shetty S
    Blood Cells Mol Dis; 2014 Sep; 53(3):161-3. PubMed ID: 24824129
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of a genetically engineered mouse model of hemophilia A with complete deletion of the F8 gene.
    Chao BN; Baldwin WH; Healey JF; Parker ET; Shafer-Weaver K; Cox C; Jiang P; Kanellopoulou C; Lollar P; Meeks SL; Lenardo MJ
    J Thromb Haemost; 2016 Feb; 14(2):346-55. PubMed ID: 26588198
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factor VIII gene (F8) mutation and risk of inhibitor development in nonsevere hemophilia A.
    Eckhardt CL; van Velzen AS; Peters M; Astermark J; Brons PP; Castaman G; Cnossen MH; Dors N; Escuriola-Ettingshausen C; Hamulyak K; Hart DP; Hay CR; Haya S; van Heerde WL; Hermans C; Holmström M; Jimenez-Yuste V; Keenan RD; Klamroth R; Laros-van Gorkom BA; Leebeek FW; Liesner R; Mäkipernaa A; Male C; Mauser-Bunschoten E; Mazzucconi MG; McRae S; Meijer K; Mitchell M; Morfini M; Nijziel M; Oldenburg J; Peerlinck K; Petrini P; Platokouki H; Reitter-Pfoertner SE; Santagostino E; Schinco P; Smiers FJ; Siegmund B; Tagliaferri A; Yee TT; Kamphuisen PW; van der Bom JG; Fijnvandraat K;
    Blood; 2013 Sep; 122(11):1954-62. PubMed ID: 23926300
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Source and purity of factor VIII products as risk factors for inhibitor development in patients with hemophilia A.
    Mancuso ME; Mannucci PM; Rocino A; Garagiola I; Tagliaferri A; Santagostino E
    J Thromb Haemost; 2012 May; 10(5):781-90. PubMed ID: 22452823
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factor VIII gene (F8) mutations as predictors of outcome in immune tolerance induction of hemophilia A patients with high-responding inhibitors.
    Coppola A; Margaglione M; Santagostino E; Rocino A; Grandone E; Mannucci PM; Di Minno G;
    J Thromb Haemost; 2009 Nov; 7(11):1809-15. PubMed ID: 19740093
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mild hemophilia A patient with novel Pro1809Leu mutation develops an anti-C2 antibody inhibiting allogeneic but not autologous factor VIII activity.
    Yada K; Nogami K; Takeyama M; Ogiwara K; Wakabayashi H; Shima M
    J Thromb Haemost; 2015 Oct; 13(10):1843-53. PubMed ID: 26278069
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factor VIII cross-matches to the human proteome reduce the predicted inhibitor risk in missense mutation hemophilia A.
    Hart DP; Uzun N; Skelton S; Kakoschke A; Househam J; Moss DS; Shepherd AJ
    Haematologica; 2019 Mar; 104(3):599-608. PubMed ID: 30266735
    [TBL] [Abstract][Full Text] [Related]  

  • 15. To serve and protect: The modulatory role of von Willebrand factor on factor VIII immunogenicity.
    Hartholt RB; van Velzen AS; Peyron I; Ten Brinke A; Fijnvandraat K; Voorberg J
    Blood Rev; 2017 Sep; 31(5):339-347. PubMed ID: 28716211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The incidence of inhibitor development according to specific mutations--and treatment?
    Goodeve A
    Blood Coagul Fibrinolysis; 2003 Jun; 14 Suppl 1():S17-21. PubMed ID: 14567530
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FVIII Immunogenicity-Bioinformatic Approaches to Evaluate Inhibitor Risk in Non-severe Hemophilia A.
    Hart DP
    Front Immunol; 2020; 11():1498. PubMed ID: 32849511
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Spectrum of F8 Genotype and Genetic Impact on Inhibitor Development in Patients with Hemophilia A from Multicenter Cohort Studies (J-HIS) in Japan.
    Shinozawa K; Yada K; Kojima T; Nogami K; Taki M; Fukutake K; Yoshioka A; Shirahata A; Shima M;
    Thromb Haemost; 2021 May; 121(5):603-615. PubMed ID: 33254277
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factor VIII products and inhibitor development in previously treated patients with severe or moderately severe hemophilia A: a systematic review.
    Hassan S; Cannavò A; Gouw SC; Rosendaal FR; van der Bom JG
    J Thromb Haemost; 2018 Jun; 16(6):1055-1068. PubMed ID: 29665204
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nonneutralizing antibodies against factor VIII and risk of inhibitor development in severe hemophilia A.
    Cannavò A; Valsecchi C; Garagiola I; Palla R; Mannucci PM; Rosendaal FR; Peyvandi F;
    Blood; 2017 Mar; 129(10):1245-1250. PubMed ID: 28034891
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.